Termination by Roche. In the event that Roche has exercised its First Option or its Second Option for a Compound, as applicable, and ROCHE decides to stop development or commercialisation of Compound (s) or Products for any reason, ROCHE may terminate this Agreement in its entirety or on a country-by country or Product-by Product basis at any time with six (6) months prior written notice, provided that ROCHE has offered the rights and licenses under this Agreement back to ENS by written notice and ENS has declined to accept such offer by written notice within ninety (90) days. In the event that ENS accepts the offer, the terms of this Agreement apply and regarding the transfer of data Sections 13.1.3., 13.1.4. and 13.1. 5. shall apply mutatis mutandis.
Termination by Roche without Cause After the Effective Date After the Effective Date, Roche shall have the right to terminate this Agreement at any time as a whole or on a Product-by-Product or country-by-country basis upon ninety (90) days prior written notice before First Commercial Sale in the Territory or upon one hundred eighty (180) days prior written notice after the First Commercial Sale in the Territory. The effective date of termination under this Section 18.2.2 shall be the date ninety (90) days (or one hundred eighty (180) days as the case may be) after Roche provides such written notice to Eleven.
Termination by Roche. Roche shall have the right to terminate this Agreement as a whole, or on a Product-by- Product and/or country-by-country basis, for any reason or for no reason at any time, upon ninety (90) days’ prior written notice to Emisphere. If Roche terminates this Agreement with respect to a particular Product or country, then the licenses granted to Roche under Sections 5.1(a)(i) and 5.1(a)(ii), if then in effect, shall automatically
Termination by Roche for Breach by Pieris or Pieris’ Insolvency Upon any termination by Roche for breach by Pieris or Pieris’ Insolvency, Roche and its Affiliates may upon notice retain all rights and licenses granted to Roche by Pieris under this Agreement; provided that after the effective date of termination the amounts of such payments and royalties that otherwise would have become due and payable shall continue to be due and payable to Pieris or its successor in interest (as applicable).
Termination by Roche without cause after the Research Term If Roche terminates this Agreement after the Research Term for no cause in application of Section 15.2.4, then:
Termination by Roche. (a) ROCHE shall have the right to terminate its license for a Product in the Roche Territory hereunder at any time upon thirty (30) days prior written notice to GENENTECH. If ROCHE terminates its license for a Product in the Roche Territory for other than safety reasons, ROCHE shall continue to remain liable for all of its obligations with respect to said Product, including its obligations with respect to payment of its portion of Global Development Costs, for a period of twelve (12) months from the date of the termination notice or six (6) months from the date of termination notice in the specific circumstance where GENENTECH or ROCHE has completed at least one Phase III Trial for that Product and the results of that Trial, either alone or in conjunction with any other Phase III Trial involving the Product, are insufficient to support a Registration of the Product in a country set forth on Appendix B, or if results of other preclinical or clinical trials establish that further development
Termination by Roche. (a) Roche shall have the right to terminate this Agreement in its entirety for any reason or for no reason at any time after the expiration of the Research Term upon 60 days’ prior written notice to Metabasis. *** Confidential Treatment Requested
Termination by Roche. (a) Roche may elect to cancel the development and Registration of a Product in the Field in a country located in the Licensed Territory upon one hundred eighty (180) days written notice. If Roche elects to terminate its participation in the development and Registration of a Product in the Field in a country located in the Licensed Territory, it shall use its best efforts to terminate its participation concurrently with the completion of its ongoing clinical studies. In the event that Roche elects to discontinue the development and Registration of a Product in the Field in a country located in the Licensed Territory, subject to the provisions of the D&L Agreement, Agouron and JT, their Affiliates and sublicensees shall be free, without any further action by Agouron, JT or Roche, and without any further obligation to Roche and its Affiliates, to continue to develop and/or commercialize Products in such country on their own or with any third party, and to retain, use and disclose to any such third party, information and materials which have been developed in the development and Registration of the Product, provided that Agouron and JT shall not disclose to such third party the confidential and proprietary information of Roche (other than clinical, regulatory and manufacturing information and materials specifically relating to such Product). In the event of the discontinuation of Roche's development and Registration of a Product in the Field in a country, the licenses granted to it by the provisions of Section 2.01 to use, offer for sale, sell and/or import in or into such country, such Product in the Field under applicable Agouron/JT Patent Rights and Development Program Patent Rights, and using applicable Agouron/JT Technology, Roche Technology and Development Program Technology, shall be terminated, and Agouron and JT, their Affiliates and sublicensees shall have no royalty or other obligations to Roche and its Affiliates resulting from the manufacture, use, offer for sale, sale and/or import in or into such country of the Compound, intermediates thereof and/or Products by Agouron and JT, their Affiliates and sublicensees. Subject to the provisions of the D&L Agreement: (i) Agouron and JT shall have the exclusive right to Trademarks; (ii) Roche shall transfer ownership of any Dossiers for the Product in such country to Agouron and JT; and (iii) Roche shall cooperate with Agouron and JT to affect an orderly transition of Roche's development and Registration ...
Termination by Roche. Roche may terminate this Agreement upon ninety (90) days written notice to PDL; however, any such termination prior to the end of the initial two-year term of the Research Program shall not relieve Roche of its obligations under Section 6.04 to make quarterly payments to PDL for the full two-year period provided in Section 6.01.
Termination by Roche. (a) At the end of a two-(2)-year-period from the beginning of the Research Program Roche shall have the option to terminate the Research Program by giving six (6) months prior written notice to Helicon. In addition, if the milestones set forth in Section 6.8.4 have not been achieved by Helicon for reasons not attributable to Roche, then Roche shall have the right to terminate the Agreement by giving ninety (90) days prior written notice.
